Literature DB >> 20181361

St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial.

Marcus Mannel1, Ulrike Kuhn, Ulrich Schmidt, Michael Ploch, Harald Murck.   

Abstract

Preliminary data suggest that hypericum extract LI160 is effective in atypical depression. Reported is the outcome of an 8-week double-blind, placebo-controlled, randomized trial of 600 mg LI160 vs. placebo in patients with vegetative features of atypical depression, i.e. hyperphagia or hypersomnia. One-hundred (100) patients with mild and 100 patients with moderate severity of a major depression according to ICD-10 were randomized. Patients needed to meet a score of 2 in at least one of the items 22-26 of the Hamilton-Depression-Rating-Scale (HAM-D) 28-item version and episode duration of at least 3 months. The primary outcome variable was the relative change of the HAM-D(17) from Baseline. Secondary outcome variables were the depression sub-score of the Patient Health Questionnaire (PHQ-9), the Clinical Global Impression (CGI), a patient's satisfaction scale, the Hamilton-Anxiety-Scale (HAM-A) and the sum score of atypical vegetative symptoms of the HAM-D(28). The percentage reduction of the HAM-D(17) for LI160 compared to placebo approached statistical significance (p=0.051) in the Full Analysis Set (FAS)-population. Using the conventional criterion of the absolute reduction of the HAM-D(17) significance was achieved (p<0.05). No significant benefit could be observed for the sum score of the atypical vegetative items of the HAM-D(28;) however, the sum score of the hypersomnia items (items 22-24) showed a significant superiority for LI160. The HAM-A, PHQ-9, and CGI-I scales demonstrated superiority of LI160 (p<0.01). Confining the analysis to moderately depressed patients, a highly significant benefit for the primary outcome variable was revealed. The study supports the beneficial effect of LI160 in depression with atypical features and the validity of the definition of atypical depression on the basis of reversed vegetative signs. Further, it identifies the PHQ-9 as a useful outcome variable in this population. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181361     DOI: 10.1016/j.jpsychires.2010.01.010

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  12 in total

1.  St. John's Wort for Major Depressive Disorder: A Systematic Review.

Authors:  Alicia Ruelaz Maher; Susanne Hempel; Eric Apaydin; Roberta M Shanman; Marika Booth; Jeremy N V Miles; Melony E Sorbero
Journal:  Rand Health Q       Date:  2016-05-09

Review 2.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.

Authors:  Arun V Ravindran; Lynda G Balneaves; Guy Faulkner; Abigail Ortiz; Diane McIntosh; Rachel L Morehouse; Lakshmi Ravindran; Lakshmi N Yatham; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 3.  Recent topics related to testosterone deficiency syndrome in Japan.

Authors:  Akira Tsujimura; Norio Nonomura
Journal:  Asian J Androl       Date:  2011-04-04       Impact factor: 3.285

4.  Complementary medicine in radiation oncology : German health care professionals' current qualifications and therapeutic methods.

Authors:  Kerstin A Kessel; Evelyn Klein; Carolin C Hack; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2018-08-02       Impact factor: 3.621

Review 5.  Natural products and supplements for geriatric depression and cognitive disorders: an evaluation of the research.

Authors:  Taya Varteresian; Helen Lavretsky
Journal:  Curr Psychiatry Rep       Date:  2014-08       Impact factor: 5.285

Review 6.  Dietary and botanical anxiolytics.

Authors:  Elham Alramadhan; Mirna S Hanna; Mena S Hanna; Todd A Goldstein; Samantha M Avila; Benjamin S Weeks
Journal:  Med Sci Monit       Date:  2012-04

7.  Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves.

Authors:  Déanne Malenfant; Kelly Summers; Shannon Seney; Donna McBain; Lisa Petrlich; Sharon Watson; Louise Vanderhoek; Nooshin Samadi; Ashley Bonner; Janet Pope
Journal:  ISRN Rheumatol       Date:  2011-09-12

Review 8.  A systematic review of St. John's wort for major depressive disorder.

Authors:  Eric A Apaydin; Alicia R Maher; Roberta Shanman; Marika S Booth; Jeremy N V Miles; Melony E Sorbero; Susanne Hempel
Journal:  Syst Rev       Date:  2016-09-02

Review 9.  Therapeutic Effects of Phytochemicals and Medicinal Herbs on Depression.

Authors:  Gihyun Lee; Hyunsu Bae
Journal:  Biomed Res Int       Date:  2017-04-19       Impact factor: 3.411

Review 10.  Roles of chemical complexity and evolutionary theory in some hepatic and intestinal enzymatic systems in chemical reproducibility and clinical efficiency of herbal derivatives.

Authors:  Francesco Di Pierro
Journal:  ScientificWorldJournal       Date:  2014-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.